AN
1998360072 EMBASE
TI
Moderate intake of n-3 fatty acids for 2 months has no detrimental effect
on glucose metabolism and could ameliorate the lipid profile in type 2
diabetic men: Results of a controlled study.
AU
Luo J.; Rizkalla S.W.; Vidal H.; Oppert J.-M.; Colas C.; Boussairi A.;
Guerre- Millo M.; Chapuis A.-S.; Chevalier A.; Durand G.; Slama G.
CS
G. Slama, Department of Diabetes, Hotel-Dieu, 1, place du Parvis
Notre-Dame, 75181 Paris Cedex 04, France
SO
Diabetes Care, (1998) Vol. 21, No. 5, pp. 717-724. .
Refs: 39
ISSN: 0149-5992 CODEN: DICAD2
CY
United States
DT
Journal; Article
FS
003 Endocrinology
029 Clinical Biochemistry
037 Drug Literature Index
LA
English
SL
English
ED
Entered STN: 19 Nov 1998
Last Updated on STN: 19 Nov 1998
AB
OBJECTIVE - To evaluate the effect of a moderate dose of fish oil on
glycemic control and in vivo insulin action in type 2 diabetic men with
elevated plasma triacylglycerols and to determine the effect of the same
treatment on gene expression of GLUT4, lipoprotein lipase (LPL), and
hormone- sensitive lipase (HSL) in the abdominal adipose tissue.
RESEARCH DESIGN AND METHODS - A total of 12 type 2 diabetic men were
randomly allocated to 2 months of 6 g daily of either fish oil or
sunflower oil, separated by a 2- month washout interval, in a double-blind
crossover design. RESULTS - For glucose metabolism, 2 months of fish oil
supplementation compared with sunflower oil led to similar fasting plasma
insulin, glucose, and HbA(1c). Basal hepatic glucose production did not
increase after fish oil. There was no difference in insulin suppression
of hepatic glucose production nor in insulin stimulation of whole-body
glucose disposal measured by the euglycemic-hyperinsulinemic clamp. Fish
oil did not ameliorate the low mRNA level of GLUT4 in adipose tissue of
these patients. For lipid profile, fish oil lowered plasma
triacylglycerol more than sunflower oil (P < 0.05) and tended to increase
the amount of mRNA of both LPL and HSL in adipose tissue. CONCLUSIONS -
A moderate dose of fish oil did not lead to deleterious effects on
glycemic control or whole-body insulin sensitivity in type 2 diabetic
men, with preserved triacylglycerol-lowering capacities.
CT
Medical Descriptors:
*non insulin dependent diabetes mellitus: DT, drug therapy
*fat intake
glucose homeostasis
gene expression regulation
enzyme synthesis
protein expression
glucose blood level
cholesterol blood level
lipoprotein blood level
triacylglycerol blood level
insulin blood level
human
male
clinical article
clinical trial
double blind procedure
crossover procedure
controlled study
adult
oral drug administration
article
Drug Descriptors:
*sunflower oil: CT, clinical trial
*sunflower oil: CM, drug comparison
*sunflower oil: DT, drug therapy
*omega 3 fatty acid: CT, clinical trial
*omega 3 fatty acid: CM, drug comparison
*omega 3 fatty acid: DT, drug therapy
*fish oil: CT, clinical trial
*fish oil: CM, drug comparison
*fish oil: DT, drug therapy
glucose: EC, endogenous compound
triacylglycerol: EC, endogenous compound
cholesterol: EC, endogenous compound
high density lipoprotein cholesterol: EC, endogenous compound
lipoprotein a: EC, endogenous compound
apolipoprotein a1: EC, endogenous compound
insulin: EC, endogenous compound
glucose transporter: EC, endogenous compound
lipoprotein lipase: EC, endogenous compound
RN
(sunflower oil) 8001-21-6; (fish oil) 8016-13-5; (glucose) 50-99-7,
84778-64-3; (cholesterol) 57-88-5; (insulin) 9004-10-8; (lipoprotein
lipase) 83137-80-8, 9004-02-8